SENNI MICHELE

Ostrominski, J., Vaduganathan, M., Claggett, B., Desai, A., Jhund, P., Lam, C., et al. (2026). Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial. JACC. HEART FAILURE, 14(1) [10.1016/j.jchf.2025.03.007]. Detail

Bhatt, A., Vaduganathan, M., Claggett, B., Jhund, P., Henderson, A., Lam, C., et al. (2026). Effects of Finerenone on Readmissions for Heart Failure: Insights From the FINEARTS-HF Trial. JOURNAL OF CARDIAC FAILURE, 32(1), 134-139 [10.1016/j.cardfail.2025.05.006]. Detail

Sciatti, E., Di Odoardo, L., Zucchetti, O., Senni, M., D'Elia, E. (2026). Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: A prospective pilot study. HEART, 112(1), 53-56 [10.1136/heartjnl-2025-326009]. Detail

Ostrominski, J., Mc Causland, F., Claggett, B., Desai, A., Jhund, P., Lam, C., et al. (2026). Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial. JACC. HEART FAILURE, 14(1), 1-14 [10.1016/j.jchf.2025.03.006]. Detail

Mcdowell, K., Docherty, K., Campbell, R., Henderson, A., Jhund, P., Claggett, B., et al. (2025). Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA CARDIOLOGY, 10(6), 535-544 [10.1001/jamacardio.2025.0025]. Detail